1120 SR One
BioCentury & Getty Images

Finance

SR One’s newfound freedom allows firm to increase focus on company creation

Former GSK venture arm raises $500M for first fund

SR One’s spinout from GSK gives the firm the ability to scale up investments and put more focus on keeping a larger stake in its growing company creation activities.

Nov 20, 2020 | 11:18 PM GMT

SR One’s spinout from GSK gives the newly independent VC the ability to scale up what has been a top-tier investment firm over the past decade, along with the freedom

Read the full 903 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE